5-substituted-2-arylpyrazines

Details 5-substituted-2-arylpyrazines 5-substituted-2-arylpyrazines

2007-02-20

2007-02-20

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252110, C514S255050, C514S255060, C544S120000, C544S295000, C544S405000, C544S408000

Reexamination Certificate

active

10645312

ABSTRACT:
Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators or CRF receptors. Compounds of the invention are provided by the following formula:The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphercal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

REFERENCES:
patent: 4083977 (1978-04-01), Miesel
patent: 4160834 (1979-07-01), Miesel
patent: 4211870 (1980-07-01), Barnett et al.
patent: 4293552 (1981-10-01), Miesel
patent: 4788197 (1988-11-01), Wakabayashi et al.
patent: 2003/0018035 (2003-01-01), Yoon et al.
patent: 2005/0215559 (2003-09-01), Yoon et al.
patent: 1 499 768 (1978-02-01), None
patent: 2 272 216 (1994-05-01), None
patent: 3048666 (1991-03-01), None
patent: 10-77286 (1998-03-01), None
patent: WO-95/10506 (1995-04-01), None
patent: WO-99/38829 (1998-01-01), None
patent: WO-98/11075 (1998-03-01), None
patent: WO 98/38174 (1998-09-01), None
patent: WO 98/43641 (1998-10-01), None
patent: WO 00/12488 (2000-03-01), None
patent: WO 00/45800 (2000-08-01), None
patent: WO 01/60806 (2001-08-01), None
Dautzenberg and Hauger, “The CRF peptide family and their receptors: yet more partners discovered” Trends in Phamacological Sciences, vol. 23(2), pp. 71-77 (Feb. 2002).
Kehne and De Lombaert, “Non-Peptide CRF1 Receptor Antagonists for the Treatment of Anxiety, Depression and Stress Disorders” Current Drug Targets—CNS & Neurological Disorders, vol. 1(5), pp. 467-493 (2002).
Akita et al., “Cross-coupling Reaction of Chloropyrazines with Acetylenes,” Chem. Pharm. Bull. 34:1447-1458 (1986).
Alvernhe et al., “Action De L'Acide Fluorhydrique Sur Les Azirines: Synthase D'a-Fluoroacetines et de Difluoroamines—Etude de L'Orientation de la Reaction,” Tetrahedron Letters 21:1437-1440 (1980).
Badiger et al., “Oxidative Cyclization Using Fetizone's Reagent,” Indian J. Chem. 16B:71-75 (1978).
Benincori et al., “Studies on the Fischer Indole Synthesis: Rearrangements of Five-, Six- and Seven-membered Cyclic Hydrazones of Pyrazoline, Tetrahydropyridazine and Tetrahydro-1,2-diazepine Series in Polyphosphoric Acid,” J. Chem. Soc. Perkin Trans. 1:2139-2145 (1991).
Bremmer et al., “Elevated CSF Corticotropin-Releasing Factor Concentrations in Posttraumatic Stress Disorder,” Am. J. Psychiatry 154:624-629 (1997).
Chellappa et al., “PMR Spectra of Some Substituted Pyrazines & 2,3-Dihydropyrazines,” Indian Journal of Chemistry 21B:778-779 (1982).
Hamazaki et al., “The Photoreaction of 5-Aryl-2, 3-dicyanopyrazine in the Presence of Diethylamine,” Bulletin of Science and Engineering Research Laboratory Waseda University 103:35-38 (1983).
Heinrichs et al., “Anti-Stress Action of a Corticotropin-Releasing Factor Antagonist on Behavioral Reactivity to Stressors of Varying Type and Intensity,” Neuropsychopharmacology 11:179-186 (1994).
Iredale et al., “Differential Regulation of Corticotropin-Releasing Factor1Receptor Expression by Stress and Agonist Treatments in Brain and Cultured Cells,” Molecular Pharmacology 50:1103-1110 (1996).
Kalin et al., “Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus,” Brain Research 656:182-186 (1994).
Menzaghi et al., “Characterization of a Novel and Potent Corticotropin-Releasing Factor Antagonist in Rats1,” Journal of Pharmacology and Experimental Therapeutics 269:564572 (1994).
Mitchell et al., “The Role of Corticotropin Releasing Factor in Depressive Illness: A Critical Review,” Neuroscience and Behavioral Reviews 22:635-651 (1998).
Ohta et al., “Anti-Platelet Aggregation Activity of Some Pyrazines,” Biol. Pharm. Bull 20:1076-1081 (1997).
Ohta et al., “Coupling Reaction of Chloropyrazines and their N-Oxides with Tetraphenyltin,” Heterocycles 24:785-792 (1986).
Schulz et al., “CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors,” Proc. Natl. Acad. Sci. USA 93:10477-10482 (1996).
Smagin et al., “Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats,” Neuroscience Letters 220:167-170 (1996).
Smagin et al., “CRF Receptor Antagonist Attenuates Immobilization Stres-Induced Norepinephrine Release in the Prefrontal Cortex in Rats,” Brain Research Bulletin 42:431-434 (1997).
Taylor et al., “Intramolecular Diels-Alder Reactions of 1, 2, 4-Triazines. Routes to Condensed Pyrazines via Cycloaddition of Nitrile Dienophiles,” J. Org. Chem. 54:1245-1249 (1989).
Taylor et al., “Synthesis of Pyridines by Diels-Alder Reactions of Hetero-Substituted 1, 2, 4-Triazines with Enamines and an Enaminone,” J. Org. Chem. 54:1249-1256 (1989).
Vinot et al., “No. 797.—Synthase de pyrazines,” Bulletin de la Societe Chimique de France 12:4970-4974 (1968).
Yamagami et al., “Measurement and Prediction of Hydrophobicity Parameters for Highly Lipophilic Compounds: Application of the HPLC Column-Switching Technique to Measurement of log P of Diarylpyraines,” Journal of Pharmaceutical Sciences 88;1299-1304 (1999).
CAS Printout of Hamazald et al., Chem Abs. 100:5477, (1984).
CAS Printout of Hori et al., Chem. Abs. 80:890 (1974).
CAS Printout of Inoue et al., Chem. Abs. 93:11448, (1980).
CAS Printout of McCarpra et al., Chem. Abs. 79:125387, (1973).
CAS Printout of Miescl et al., Chem. Abs. 96:35307, (1982).
CAS Printout of Rees et al., (WO 08/43641).
CAS Printout of Teranishi et al. (JP 10077286) (1998).
CAS Printout of Teranishi et al. (JP 1998-184331).
CAS Printout of Teranishi et al., Chem Abs. 114:101506, (1991).

Affiliated with

Also associated with

Rating

5-substituted-2-arylpyrazines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-substituted-2-arylpyrazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted-2-arylpyrazines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3853699